EGFR and non-small cell lung carcinoma: A pooled analysis of studies involving first-generation EGFR-TKIs in NSCLC patients with brain metastases reported an intracranial objective response rate (IC-ORR) of 51.8%, a disease control rate (DCR) of 75.7%, a median progression-free survival (PFS) of 7.4 months, and an overall survival (OS) of 11.9 months.